10/20/2026
Next up for Healthcare Quality Week: MultiCare Deaconess Hospital.
Improving health care quality means addressing some of the most pressing public health challenges facing our communities. At MultiCare Deaconess Hospital, teams are transforming care for patients with opioid use disorder (OUD) through an innovative approach that’s expanding access to evidence-based treatment and improving connections to long-term recovery.
What began as an Emergency Department pilot has evolved into a groundbreaking program that positions Deaconess as a leader in Washington state.
Today, the hospital is the only facility in Eastern Washington offering long-acting injectable buprenorphine (LAIB) in the Emergency Department, and the first and only hospital in Washington to provide LAIB treatment for eligible patients during inpatient hospitalization.
This important advancement in OUD treatment helps patients stay on track with daily medication while creating opportunities for sustained engagement in recovery services. By initiating treatment at critical points of care, clinicians can help patients move from acute settings to ongoing community-based support.
Since February 2026, Deaconess has administered 46 doses of Brixadi to 44 unique Emergency Department patients. Building on that success, the program expanded to inpatient care in July 2026, where 13 doses have already been administered to 11 patients, including antepartum and postpartum patients with complex healthcare needs.
The results are remarkable. Since implementing LAIB, patients who received the injection have:
-- Reduced their Emergency Department utilization across Inland Northwest hospitals by 60%.
--Decreased their Emergency Department utilization within MultiCare facilities by 65%.
--Engaged in their in community follow-up care at a rate of 70%.
--Shrunk hospital write-offs by $600,000.
These results demonstrate the power of treating opioid use disorder as a chronic health condition that benefits from timely, evidence-based intervention and strong community partnerships.
Participation in the Braeburn Hospital Initiation Free Trial (BIFT) accelerated this work by supporting access to inpatient LAIB treatment while strengthening hospital and community provider collaboration. The initiative helps ensure patients can begin treatment during hospitalization and leave connected to ongoing recovery resources.
Most importantly, this work reflects a commitment to health equity, innovation and patient-centered care. By integrating long-acting injectable buprenorphine across emergency and inpatient settings, Deaconess is helping reshape how healthcare systems respond to opioid use disorder.
The program offers a promising path to keep patients in treatment, support recovery, prevent avoidable hospital visits and strengthen communities.
As we celebrate Healthcare Quality Week, Deaconess exemplifies innovative care, multidisciplinary teamwork and a relentless focus on patient needs. Their work is driving better health outcomes, showing how improved care processes can create lasting positive changes for patients, families and communities across Washington.